Determination of the Aldosterone/Renin Ratio in 269 Patients with Adrenal Incidentaloma

Abstract

To determine the prevalence of primary aldo-steronism among patients with incidentally discovered adrenal adenomas (‘incidentalomas’) plasma concentrations of aldosterone (PA) and plasma renin activity (PRA) were determined in 269 patients (100 normotensives, 169 hypertensives) newly referred incidentaloma patients. Among the 100 normotensives a PA [ng/dl]/PRA [ng/ml.h]-ratio (A/R-R) >50 and a concomitant elevation of PA (>15 pg/ml) was initially seen in two cases but further investigations excluded the presence of primary aldosteronism in both patients suggesting a prevalence of primary aldosteronism of <1% among normotensive patients with adrenal incidentaloma. Among the 169 hypertensive incidentaloma patients 14 presented with both, an elevated PA [>15 pg/ml] and an A/R-R >50. Primary aldosteronism was confirmed in 6 of this cases resulting in a prevalence of primary aldosteronism among hypertensive incidentaloma patients of 4%. Although obtained in patients with a supposedly high pre-test probability of primary aldosteronism this percentage - while in keeping with the older literature - is surprisingly low given the recently reported large(r) prevalence of primary aldosteronism among hypertensives in general.

Aldosterone - adrenal - renin

References

• 1 Ross NS, Aron DC. Hormonal evaluation of the patient with an incidentally discovered adrenal mass.  N Engl J Med. 1990;  323 1402-1405
• 2 Rosen HN, Swartz SL. Subtle glucocorticoid excess in patients with adrenal incidentaloma.  Am J Med. 1992;  92 213-216
• 3 Gross MD, Shapiro B. Clinical review 50: clinically silent adrenal masses.  J Clin Endocrinol Metab. 1993;  77 885-888
• 4 Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients.  Arch Intern Med. 1981;  141 1589-1593
• 5 Loh KC, Koay ES, Khwa MC, Emmanuel SC, Young WF. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore.  J Clin Endocrinol Metab.. 2000;  85 2854-2859
• 6 Bravo EL, Tarazi RC, Dustan HP, Fouad FM, Textor C, Gifford RW, Vidt DG. The changing clinical spectrum of primary aldosteronism.  Am J Med. 1983;  74 641-651
• 7 Streeten DHP, Tomycz N, Anderson GH Jr. Reliability of screening methods for the diagnosis of primary aldosteronism.  Am J Med. 1979;  67 403-413
• 8 Weinberger MH, Grim CE, Hollifield JW, Kem DC, Ganguly A, Kramer NJ, Yune HY, Wellman H, Donohue JP. Primary aldosteronism: diagnosis, localization, and treatment.  Ann Intern Med. 1979;  90 386-395
• 9 McKenna TJ, Sequeira SJ, Heffernan A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism.  J Clin Endocrinol Metab. 1991;  73 952-957
• 10 Montori VM, Young WF. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism - A systematic review of the literature.  Endorcinol Metab Clin N Amer. 2002;  31 619-632
• 11 Lim PO, Cardale K, Watson AD, MacDonnell TM. Potentially high prevalence of primary aldosteronism in a primary-care population.  Lancet. 1999;  353 40
• 12 Fardella CE, Mosso L, Gomezsanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Mantero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology.  J Clin Endocrinol Metab. 2000;  85 1863-1867
• 13 Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomezsanchez CE, Veglio F, Young WF. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.  J Clin Endocrinol Metab. 2004;  89 1045-1050
• 14 Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol.  J Hypertens. 2006;  24 737-745
• 15 Bernini G, Moretti A, Argenio G, Salvetti A. Primary aldosteronism in normokalemic patients with adrenal incidentalomas.  Eur J Endocrinology. 2002;  146 523-529
• 16 Zipser RD, Speckart PF. ‘Normotensive’ primary aldosteronism.  Ann Intern Med. 1978;  88 655-666
• 17 Kono T, Ikeda F, Oseko F, Imura H, Tanimura H. Normotensice primary aldosteronism: Report of a case.  J Clin Endocrinol Metab. 1981;  52 1009-1013
• 18 Gessl A, Vierhapper H. Development of hypertension in a patient with initially normotensive primary aldosteronism.  , Abstracts, 84th Annual Meeting of the Endocrine Society, San Francisco, June 19-21, 2002;P3-463.y
• 19 Kaplan NM. Cautions over the current epidemic of primary aldosteronism.  Lancet. 2001;  357 953-954

Correspondence